Switzerland· 66380002

Bavencio

A avelumab product containing avelumabum, registered in Switzerland and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 12 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat A (Swissmedic)ATC L01FF04

Checked against BAG Spezialitätenliste (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHBAG Spezialitätenliste (Switzerland)normalisedBavencioATCL01FF04REGISTER NO.66380002PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Avelumab is registered in 12 of 19 countries.

Countries holding a registration under ATC L01FF04 (avelumab), each read from that country’s own register.

  • This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
  • 8 of them publish a price we can compare per daily dose

Avelumab · ATC L01FF04

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

BAG Spezialitätenliste (Switzerland)
Active substance
avelumabum
Manufacturer
—
Country
Switzerland (CH)
ATC code
L01FF04
ATC class
Avelumab
Defined daily dose
57.1 mg, P
Swissmedic category
A
Reimbursed
Yes
Source register
BAG Spezialitätenliste (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680663800020
    4 Durchstf 10 ml
    CHF 3139.85

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

3 interactions on record for avelumab.

Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Avelumab · interactions on record

3 records

  • 3 severe

Most severe, free to view

  • ThalidomideL04AX02severe
  • LenalidomideL04AX04severe
  • PomalidomideL04AX06severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Avelumab in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All avelumab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Bavencio
  • Liechtenstein · Bavencio
  • Norway · Bavencio

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/48a7814c-5f86-4047-9604-ea8cae99ba33
GET /v1/drugs/48a7814c-5f86-4047-9604-ea8cae99ba33?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "avelumabum 200 mg",
  "valid_from": "2025-09-01",
  "limitations": "[{\"description\":\"Die Behandlung bedarf der Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes.<br>\\n<br>\\nDie empfohlene Dosierung beträgt 10 mg/kg Körpergewicht alle zwei Wochen.<br>\\nDie Behandlung wird maximal bis zur Progression der Erkrankung oder bis zum Auftreten unzumutbarer Toxizitätserscheinungen vergütet. Die Behandlung von klinisch stabilen Patienten mit initialem Befund einer Progression wird bis zur Bestätigung der Progression der Erkrankung vergütet.<br>\\n<br>\\n<b>Metastasiertes Merkelzellkarzinom</b><br>\\nZur Behandlung von Patienten mit metastasiertem Merkelzellkarzinom (MCC). Patienten mit vorgängiger anti-PD-1 oder anti-PD-L1-Therapie sind von der Vergütung ausgeschlossen.<br>\\n<br>\\n<b>Lokal fortgeschrittenes oder metastasiertes Urothelkarzinom</b><br>\\nAls Monotherapie zur Erstlinien-Erhaltungstherapie bei Patienten mit lokal fortgeschrittenem oder metastasiertem Urothelkarzinom (UC), deren Erkrankung unter einer platinbasierten Erstlinien-Induktionschemotherapie nicht fortgeschritten ist.<br>\\n<br>\",\"costApproval\":null,\"indication\":\"\",\"isNew\":false,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2025-09-01\",\"validTo\":null}]",
  "galenic_form": "Inf Konz 200 mg/10 ml",
  "therapeutic_area": null,
  "sl_inclusion_date": "2021-03-01",
  "self_retention_pct": 10
}

See everything about avelumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.